



Medicine Supply Notification

MSN/2025/067

Sotrovimab (Xevudy®) 500mg/8ml solution for infusion vials

Tier 2 – medium impact*

Date of issue: 15/12/2025

Link: [Medicines Supply Tool](#)

Summary

- Sotrovimab (Xevudy®) 500mg/8ml solution for infusion vials are being discontinued from late February 2026. All remaining UK stock expires in February 2026.
- Alternative COVID-19 treatments remain available.

Actions Required

NHS provider Trust pharmacy procurement teams should check locally to ascertain stock availability and can continue to order remaining stock of sotrovimab 500mg/8ml solution for infusion vials via the regional pharmacy procurement leads until the stock is exhausted.

Once stocks are exhausted, clinicians should consider prescribing alternative COVID-19 treatments in line with [NICE guidance](#), ensuring the patient is not intolerant to any of the excipients.

If the above options are not considered appropriate, or for patients with acute porphyrias, advice should be sought from specialist teams on management options (See Supporting Information).

Supporting information

Sotrovimab is licensed for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection.

Patients with acute porphyrias

According to the UK Porphyria Medicine Information Service (UKPMIS) [SAFE LIST](#) of drugs that are considered to be safe for use in the acute porphyrias, only sotrovimab is listed under COVID-19 treatments. For information on medication not listed, and for advice on other complex treatment scenarios, UKPMIS can be contacted on 029 2003 2011 or email: welshmedicines.information@wales.nhs.uk.

Links to further information

[BNF: Sotrovimab](#)

[SmPC: Xevudy® 500 mg concentrate for solution for infusion](#)

[NICE: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#)

[UKPMIS: Drugs that are considered to be safe for use in the acute porphyrias](#)

[BNF: Acute porphyrias](#)

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Specialist Pharmacy Service Regional Pharmacy Procurement Team, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands	Andi Swain	andi.swain@nhs.net	Dav Manku	Dav.Manku@uhb.nhs.uk
East of England	James Kent	james.kent@nhs.net	Tracy McMillan	tracy.mcmillan2@nhs.net
London	Jackie Eastwood	j.eastwood@nhs.net	Daniel Johnson	Daniel.Johnson@nhs.net
North East and Yorkshire	David Allwood	davidallwood@nhs.net	Penny Daynes	penny.daynes@nhs.net
North West	Richard Bateman	richard.bateman@liverpoolft.nhs.uk	Andy Stewart	Andrew.stewart@liverpoolft.nhs.uk
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk	Melanie Renney	melanie.renney@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk	Natalie Bryson	Natalie.Bryson@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2025/067.

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.